Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

2024 Scrip Asia 100 - Japan
Scrip Asia 100 logo

2024 Scrip Asia 100

Latest Updates And Considerations In Asia Pacific


Japanese firms prioritize expansion in the US market, exhibiting high rates of complex CNS and oncology R&D success. Back home, drug shortages continue for type 2 diabetes.

What's Behind Japan Firms' Higher Approval Rates In Challenging Oncology, CNS Areas?

Despite a global tendency for lower than average success rates from Phase I to approval in the challenging oncology and CNS areas, a recent Citeline study finds top Japanese pharma firms have relatively high rates in these two categories in the US. So what are the factors driving those differences?

Research & Development Strategy Cancer

Japan Faces GLP-1 Shortage As Off-Label Diet Use Surges

Despite repeated warnings by regulatory authorities and physicians’ associations, the demand for easy diet aids is impacting the supply of GLP-1 receptor antagonists in Japan.

Japan Supply Chain Metabolic Disorders